Introduces Full Year 2021 Earnings Guidance
|
Three Months Ended |
|
Year Ended |
|||||||||||
|
|
|
|
|||||||||||
|
2020 |
|
2019 |
|
2020 |
|
2019 |
|||||||
|
|
|
|
|
|
|
|
|||||||
|
(In millions, except per share results) |
|||||||||||||
Premium Revenue |
|
|
|
|
|
|
|
|
|
|
|
|||
Total Revenue |
|
|
|
|
|
|
|
|
|
|
|
|||
Pre-Tax Income |
|
|
|
|
|
|
|
|
|
|
|
|||
Net Income |
|
|
|
|
|
|
|
|
|
|
|
|||
GAAP EPS – Diluted |
|
|
|
|
|
|
|
|
|
|
|
|||
Adjusted EPS – Diluted (1) |
( |
|
|
|
|
|
|
|
|
|
|
|||
Normalized EPS - Diluted (1) |
|
|
|
— |
|
|
|
|
|
— |
|
|||
GAAP Ratios: |
|
|
|
|
|
|
|
|
|
|
||||
MCR |
90.8 |
% |
|
|
86.0 |
% |
|
|
86.5 |
% |
|
|
85.8 |
% |
G&A Ratio |
8.6 |
% |
|
|
8.0 |
% |
|
|
7.6 |
% |
|
|
7.7 |
% |
Effective Tax Rate |
33.8 |
% |
|
|
24.3 |
% |
|
|
30.0 |
% |
|
|
24.2 |
% |
After-Tax Margin |
0.6 |
% |
|
|
3.9 |
% |
|
|
3.5 |
% |
|
|
4.4 |
% |
(1) Description and reconciliation of non-GAAP financial measures on pages 11-12 of this release. |
Full Year Highlights
-
Total revenue increased 15% to
$19.4 billion for the full year 2020 compared to 2019. -
For the full year 2020, net income was
$673 million , or$11.23 per diluted share, compared to net income of$737 million , or$11.47 per diluted share, for the full year 2019. -
Results were positively impacted by adjustments of
$0.56 per diluted share for the full year 2020. -
The net effect of COVID decreased net income for the full year 2020 by
$2.30 per diluted share. -
Full year 2020 normalized EPS, representing adjusted EPS and excluding the net effect of COVID, was
$12.97 per diluted share. -
The Company issued its full year 2021 earnings guidance, with premium revenue growth expected to be over 25% and adjusted EPS expected to be in the range of
$12.50 -$13.00 . - Included in the Company’s guidance is the effect of the overhang from COVID and Medicare risk scores expected to soon abate. When combined with the attainment of targeted margins on recent acquisitions, the Company expects an increase of several dollars in EPS in future periods.
“2020 presented an unprecedented environment, and I am proud of our performance as we focused on delivering for all of our stakeholders. We ensured our members had access to high quality care, we implemented innumerable special protocols for providers and our state customers, and we delivered growth and excellent financial results,” said
Total Revenue
For the year ended
Net Income
For the year ended
For the full year 2020, the Company’s normalized EPS was
Medical Care Ratio
The consolidated MCR for the year ended
General and Administrative Expense Ratio
For the year ended
Balance Sheet
Cash and investments at the parent company amounted to
In
Cash Flow
Operating cash flow for the year ended
2021 Guidance
The Company issued its full year 2021 earnings guidance, with premium revenue growth expected to be over 25% and adjusted EPS expected to be in the range of
Full year guidance reflects the following expected positive drivers:
- Continued strong performance in Medicaid and Medicare;
- Margin recovery and growth in the Marketplace business;
-
Accretion from the Magellan Complete Care businesses and the
Kentucky and Passport installation; and, - The elimination of the Health Insurer Fee.
Full year guidance considers the following industry-wide and economic environment challenges that are expected to be mostly temporary, including:
- A negative net effect of COVID due to a continuation of many of the risk-sharing corridors that existed in 2020 and the direct costs of COVID-related patient care;
- Medicare risk scores; and,
- Net pharmacy benefit carve-outs.
Full year guidance does not include:
- The Affinity acquisition, as the transaction has not yet closed; and,
-
The impact of potential Public Health Emergency extensions beyond
mid-April 2021 .
Included in the Company’s guidance is the effect of the overhang from COVID and Medicare risk scores expected to soon abate. When combined with the attainment of targeted margins on recent acquisitions, the Company expects an increase of several dollars in EPS in future periods.
The Company has posted a presentation entitled “4Q20 Earnings Supplement,” dated
Full Year 2021 Guidance (1) |
|
Premium Revenue |
> |
Total Revenue |
> |
GAAP Net Income |
|
Adjusted Net Income (2) |
|
GAAP EPS – Diluted |
|
Adjusted EPS – Diluted (2) |
|
Diluted weighted average shares |
~58.5M |
|
|
Year End Total Membership |
~3.9M |
Medicaid and Medicare |
~3.5M |
Marketplace |
~400K |
|
|
MCR |
~88.0% |
GAAP G&A Ratio |
~7.3% |
Adjusted G&A Ratio (2) |
~7.0% |
Effective Tax Rate |
~25.6% |
GAAP After-tax Margin |
~2.7% |
Adjusted After-tax Margin (2) |
~3.0% |
(1) All amounts are rounded and approximations. (2) Reconciliations of non-GAAP financial measures on page 13 of this release. |
Conference Call
Management will host a conference call and webcast to discuss Molina Healthcare’s fourth quarter and year-end 2020 results at
About
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This earnings release and the Company’s accompanying oral remarks contain forward-looking statements regarding its 2021 guidance, as well as its plans, expectations, and the Company’s expectations regarding future developments. Actual results could differ materially due to numerous known and unknown risks and uncertainties. These risks and uncertainties are discussed under the headings “Forward-Looking Statements,” and “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended
These reports can be accessed under the investor relations tab of the Company’s website or on the SEC’s website at sec.gov. Given these risks and uncertainties, the Company can give no assurances that its forward-looking statements will prove to be accurate, or that any other results or developments projected or contemplated by its forward-looking statements will in fact occur, and the Company cautions investors not to place undue reliance on these statements. All forward-looking statements in this release represent the Company’s judgment as of
|
|||||||||||||||
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME |
|||||||||||||||
|
|
|
|
||||||||||||
|
Three Months Ended |
|
Year Ended |
||||||||||||
|
|
|
|
||||||||||||
|
2020 |
|
2019 |
|
2020 |
|
2019 |
||||||||
|
|
|
|
|
|
|
|
||||||||
|
(In millions, except per-share amounts) |
||||||||||||||
Revenue: |
|
|
|
|
|
|
|
||||||||
Premium revenue |
$ |
4,855 |
|
|
$ |
4,123 |
|
|
$ |
18,299 |
|
|
$ |
16,208 |
|
Premium tax revenue |
172 |
|
|
122 |
|
|
649 |
|
|
489 |
|
||||
Health insurer fees reimbursed |
65 |
|
|
— |
|
|
271 |
|
|
— |
|
||||
Marketplace risk corridor judgment |
128 |
|
|
— |
|
|
128 |
|
|
— |
|
||||
Investment income and other revenue |
15 |
|
|
29 |
|
|
76 |
|
|
132 |
|
||||
Total revenue |
5,235 |
|
|
4,274 |
|
|
19,423 |
|
|
16,829 |
|
||||
Operating expenses: |
|
|
|
|
|
|
|
||||||||
Medical care costs |
4,408 |
|
|
3,545 |
|
|
15,820 |
|
|
13,905 |
|
||||
General and administrative expenses |
450 |
|
|
343 |
|
|
1,480 |
|
|
1,296 |
|
||||
Premium tax expenses |
172 |
|
|
122 |
|
|
649 |
|
|
489 |
|
||||
Health insurer fees |
68 |
|
|
— |
|
|
277 |
|
|
— |
|
||||
Depreciation and amortization |
24 |
|
|
21 |
|
|
88 |
|
|
89 |
|
||||
Other |
22 |
|
|
1 |
|
|
31 |
|
|
6 |
|
||||
Total operating expenses |
5,144 |
|
|
4,032 |
|
|
18,345 |
|
|
15,785 |
|
||||
Operating income |
91 |
|
|
242 |
|
|
1,078 |
|
|
1,044 |
|
||||
Other expenses, net: |
|
|
|
|
|
|
|
||||||||
Interest expense |
30 |
|
|
20 |
|
|
102 |
|
|
87 |
|
||||
Other expense (income), net |
10 |
|
|
— |
|
|
15 |
|
|
(15) |
|
||||
Total other expenses, net |
40 |
|
|
20 |
|
|
117 |
|
|
72 |
|
||||
Income before income tax expense |
51 |
|
|
222 |
|
|
961 |
|
|
972 |
|
||||
Income tax expense |
17 |
|
|
54 |
|
|
288 |
|
|
235 |
|
||||
Net income |
$ |
34 |
|
|
$ |
168 |
|
|
$ |
673 |
|
|
$ |
737 |
|
|
|
|
|
|
|
|
|
||||||||
Net income per share - Diluted |
$ |
0.56 |
|
|
$ |
2.67 |
|
|
$ |
11.23 |
|
|
$ |
11.47 |
|
|
|
|
|
|
|
|
|
||||||||
Diluted weighted average shares outstanding |
59.4 |
|
|
63.0 |
|
|
59.9 |
|
|
64.2 |
|
||||
|
|
|
|
|
|
|
|
||||||||
Operating Statistics: |
|
|
|
|
|
|
|
||||||||
Medical care ratio |
90.8 |
% |
|
86.0 |
% |
|
86.5 |
% |
|
85.8 |
% |
||||
G&A ratio |
8.6 |
% |
|
8.0 |
% |
|
7.6 |
% |
|
7.7 |
% |
||||
Premium tax ratio |
3.4 |
% |
|
2.9 |
% |
|
3.4 |
% |
|
2.9 |
% |
||||
Effective income tax rate |
33.8 |
% |
|
24.3 |
% |
|
30.0 |
% |
|
24.2 |
% |
||||
After-tax margin |
0.6 |
% |
|
3.9 |
% |
|
3.5 |
% |
|
4.4 |
% |
|
|||||||
CONSOLIDATED BALANCE SHEETS |
|||||||
|
|
||||||
|
|
||||||
|
2020 |
|
2019 |
||||
|
Unaudited |
|
|
||||
|
(Dollars in millions,
|
||||||
ASSETS |
|||||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
4,154 |
|
|
$ |
2,452 |
|
Investments |
1,875 |
|
|
1,946 |
|
||
Receivables |
1,672 |
|
|
1,406 |
|
||
Prepaid expenses and other current assets |
175 |
|
|
163 |
|
||
Total current assets |
7,876 |
|
|
5,967 |
|
||
Property, equipment, and capitalized software, net |
391 |
|
|
385 |
|
||
|
941 |
|
|
172 |
|
||
Restricted investments |
136 |
|
|
79 |
|
||
Deferred income taxes |
69 |
|
|
79 |
|
||
Other assets |
119 |
|
|
105 |
|
||
Total assets |
$ |
9,532 |
|
|
$ |
6,787 |
|
|
|
|
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|||||||
Current liabilities: |
|
|
|
||||
Medical claims and benefits payable |
$ |
2,696 |
|
|
$ |
1,854 |
|
Amounts due government agencies |
1,253 |
|
|
664 |
|
||
Accounts payable, accrued liabilities and other |
641 |
|
|
502 |
|
||
Deferred revenue |
375 |
|
|
249 |
|
||
Total current liabilities |
4,965 |
|
|
3,269 |
|
||
Long-term debt |
2,127 |
|
|
1,237 |
|
||
Finance lease liabilities |
225 |
|
|
231 |
|
||
Other long-term liabilities |
119 |
|
|
90 |
|
||
Total liabilities |
7,436 |
|
|
4,827 |
|
||
Stockholders’ equity: |
|
|
|
||||
Common stock, |
— |
|
|
— |
|
||
Preferred stock, |
— |
|
|
— |
|
||
Additional paid-in capital |
199 |
|
|
175 |
|
||
Accumulated other comprehensive income |
37 |
|
|
4 |
|
||
Retained earnings |
1,860 |
|
|
1,781 |
|
||
Total stockholders’ equity |
2,096 |
|
|
1,960 |
|
||
Total liabilities and stockholders’ equity |
$ |
9,532 |
|
|
$ |
6,787 |
|
|
|
|
|
|
|||||||
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
|||||||
|
|
||||||
|
Year Ended |
||||||
|
|
||||||
|
2020 |
|
2019 |
||||
|
|
|
|
||||
|
(In millions) |
||||||
Operating activities: |
|
|
|
||||
Net income |
$ |
673 |
|
|
$ |
737 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
||||
Depreciation and amortization |
88 |
|
|
89 |
|
||
Deferred income taxes |
(19) |
|
|
10 |
|
||
Share-based compensation |
57 |
|
|
39 |
|
||
Loss (gain) on debt repayment |
15 |
|
|
(15) |
|
||
Other, net |
12 |
|
|
— |
|
||
Changes in operating assets and liabilities: |
|
|
|
||||
Receivables |
(100) |
|
|
(76) |
|
||
Prepaid expenses and other current assets |
(16) |
|
|
28 |
|
||
Medical claims and benefits payable |
544 |
|
|
(107) |
|
||
Amounts due government agencies |
446 |
|
|
(303) |
|
||
Accounts payable, accrued liabilities and other |
78 |
|
|
2 |
|
||
Deferred revenue |
126 |
|
|
38 |
|
||
Income taxes |
(14) |
|
|
(15) |
|
||
Net cash provided by operating activities |
1,890 |
|
|
427 |
|
||
Investing activities: |
|
|
|
||||
Purchases of investments |
(670) |
|
|
(2,536) |
|
||
Proceeds from sales and maturities of investments |
1,097 |
|
|
2,302 |
|
||
Net cash paid in business combinations |
(755) |
|
|
— |
|
||
Purchases of property, equipment, and capitalized software |
(74) |
|
|
(57) |
|
||
Other, net |
2 |
|
|
(2) |
|
||
Net cash used in investing activities |
(400) |
|
|
(293) |
|
||
Financing activities: |
|
|
|
||||
Proceeds from senior notes offerings, net of issuance costs |
1,429 |
|
|
— |
|
||
Common stock purchases |
(606) |
|
|
(47) |
|
||
Repayment of term loan facility |
(600) |
|
|
— |
|
||
Proceeds from borrowings under term loan facility |
380 |
|
|
220 |
|
||
Repayment of senior notes |
(338) |
|
|
— |
|
||
Cash paid for partial termination of warrants |
(30) |
|
|
(514) |
|
||
Cash paid for partial settlement of conversion option |
(27) |
|
|
(578) |
|
||
Cash received for partial settlement of call option |
27 |
|
|
578 |
|
||
Repayment of principal amount of convertible senior notes |
(12) |
|
|
(240) |
|
||
Other, net |
2 |
|
|
29 |
|
||
Net cash provided by (used in) financing activities |
225 |
|
|
(552) |
|
||
Net increase (decrease) in cash, cash equivalents, and restricted cash and cash equivalents |
1,715 |
|
|
(418) |
|
||
Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period |
2,508 |
|
|
2,926 |
|
||
Cash, cash equivalents, and restricted cash and cash equivalents at end of period |
$ |
4,223 |
|
|
$ |
2,508 |
|
|
|||||
UNAUDITED HEALTH PLANS SEGMENT DATA |
|||||
(Dollars in millions) |
|||||
|
|
||||
|
As of |
||||
|
2020 |
|
2019 |
||
Ending Membership(1) by Government Program: |
|
|
|
||
Medicaid |
3,599,000 |
|
|
2,956,000 |
|
Medicare |
115,000 |
|
|
101,000 |
|
Marketplace |
318,000 |
|
|
274,000 |
|
Total |
4,032,000 |
|
|
3,331,000 |
|
|
|
|
|
||
Ending Membership(1) by Health Plan: |
|
|
|
||
|
593,000 |
|
|
565,000 |
|
|
140,000 |
|
|
132,000 |
|
|
302,000 |
|
|
224,000 |
|
|
337,000 |
|
|
— |
|
|
400,000 |
|
|
362,000 |
|
|
352,000 |
|
|
288,000 |
|
|
357,000 |
|
|
341,000 |
|
|
977,000 |
|
|
832,000 |
|
Other (2) |
574,000 |
|
|
587,000 |
|
Total |
4,032,000 |
|
|
3,331,000 |
|
__________________
(1) Does not include approximately 200,000 Magellan Complete Care members from the acquisition closed on
(2) “Other” includes the |
|
Three Months Ended |
|||||||||||||||||||||
|
2020 |
|
2019 |
|||||||||||||||||||
|
Premium
|
|
Medical
|
|
MCR (1) |
|
Premium
|
|
Medical
|
|
MCR (1) |
|||||||||||
|
|
|
|
|
|
|||||||||||||||||
Medicaid |
$ |
3,850 |
|
|
$ |
3,473 |
|
|
90.2 |
% |
|
$ |
3,227 |
|
|
$ |
2,818 |
|
|
87.3 |
% |
|
Medicare |
616 |
|
|
598 |
|
|
97.1 |
|
|
561 |
|
|
480 |
|
|
85.5 |
|
|||||
Marketplace |
389 |
|
|
337 |
|
|
86.6 |
|
|
335 |
|
|
247 |
|
|
73.5 |
|
|||||
Consolidated |
$ |
4,855 |
|
|
$ |
4,408 |
|
|
90.8 |
% |
|
$ |
4,123 |
|
|
$ |
3,545 |
|
|
86.0 |
% |
|
|
Year Ended |
|||||||||||||||||||||
|
2020 |
|
2019 |
|||||||||||||||||||
|
Premium
|
|
Medical
|
|
MCR (1) |
|
Premium
|
|
Medical
|
|
MCR (1) |
|||||||||||
|
|
|
|
|
|
|||||||||||||||||
Medicaid |
$ |
14,265 |
|
|
$ |
12,461 |
|
|
87.4 |
% |
|
$ |
12,466 |
|
|
$ |
10,969 |
|
|
88.0 |
% |
|
Medicare |
2,512 |
|
|
2,161 |
|
|
86.0 |
|
|
2,243 |
|
|
1,913 |
|
|
85.3 |
|
|||||
Marketplace |
1,522 |
|
|
1,198 |
|
|
78.7 |
|
|
1,499 |
|
|
1,023 |
|
|
68.2 |
|
|||||
Consolidated |
$ |
18,299 |
|
|
$ |
15,820 |
|
|
86.5 |
% |
|
$ |
16,208 |
|
|
$ |
13,905 |
|
|
85.8 |
% |
|
__________________ (1) The MCR represents medical costs as a percentage of premium revenue. |
CHANGE IN MEDICAL CLAIMS AND BENEFITS PAYABLE
(Dollars in millions)
The Company’s claims liabilities include additional reserves to account for moderately adverse conditions based on historical experience and other factors including, but not limited to, variations in claims payment patterns, changes in utilization and cost trends, known outbreaks of disease, and large claims. The Company’s reserving methodology is consistently applied across all periods presented. The amounts displayed for “Components of medical care costs related to: Prior year” represent the amounts by which the original estimates of claims and benefits payable at the beginning of the year were more than the actual liabilities based on information (principally the payment of claims) developed since those liabilities were first reported. The following table presents the components of the change in medical claims and benefits payable for the periods indicated:
|
Year Ended |
||||||
|
|
||||||
|
2020 |
|
2019 |
||||
|
|
|
|
||||
|
Unaudited |
||||||
Medical claims and benefits payable, beginning balance |
$ |
1,854 |
|
|
$ |
1,961 |
|
Components of medical care costs related to: |
|
|
|
||||
Current year |
15,939 |
|
|
14,176 |
|
||
Prior year |
(119) |
|
|
(271) |
|
||
Total medical care costs |
15,820 |
|
|
13,905 |
|
||
Payments for medical care costs related to: |
|
|
|
||||
Current year |
13,871 |
|
|
12,554 |
|
||
Prior year |
1,507 |
|
|
1,482 |
|
||
Total paid |
15,378 |
|
|
14,036 |
|
||
Acquisition - Magellan Complete Care |
294 |
|
|
— |
|
||
Change in non-risk and other provider payables |
106 |
|
|
24 |
|
||
Medical claims and benefits payable, ending balance |
$ |
2,696 |
|
|
$ |
1,854 |
|
|
|
|
|
||||
Days in claims payable, fee for service (1) |
50 |
|
|
50 |
|
||
______________________
(1) Claims payable includes primarily claims incurred but not paid, or IBNP. It also includes certain fee-for-service payables reported in medical claims and benefits payable amounting to |
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES
(In millions)
The Company believes that certain non-generally accepted accounting principles, or non-GAAP, financial measures are useful supplemental measures to investors in comparing the Company’s performance to the performance of other public companies in the health care industry. These non-GAAP financial measures, presented below, should be considered as supplements to, and not as substitutes for or superior to, GAAP measures.
Earnings before interest, taxes, depreciation and amortization (“EBITDA”) represents GAAP net income less depreciation and amortization, interest expense and income tax expense. The Company believes that EBITDA is helpful to investors in assessing the Company’s ability to meet the cash demands of its operating units.
|
Three Months Ended |
|
Year Ended |
||||||||||||
|
|
|
|
||||||||||||
|
2020 |
|
2019 |
|
2020 |
|
2019 |
||||||||
Net income |
$ |
34 |
|
|
$ |
168 |
|
|
$ |
673 |
|
|
$ |
737 |
|
Adjustments: |
|
|
|
|
|
|
|
||||||||
Depreciation and amortization |
24 |
|
|
21 |
|
|
88 |
|
|
89 |
|
||||
Interest expense |
30 |
|
|
20 |
|
|
102 |
|
|
87 |
|
||||
Income tax expense |
17 |
|
|
54 |
|
|
288 |
|
|
235 |
|
||||
EBITDA |
$ |
105 |
|
|
$ |
263 |
|
|
$ |
1,151 |
|
|
$ |
1,148 |
|
|
|
|
|
|
|
|
|
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES CONTINUED
(In millions, except per diluted share amounts)
Adjustments represent additions and deductions to GAAP net income as indicated in the table below, which include the non-cash impact of amortization of purchased intangibles and the impact of certain expenses and other items that management believes are not indicative of longer-term business trends and operations.
Adjusted net income (loss) represents GAAP net income recognizing the adjustments, net of tax. The Company believes that adjusted net income is helpful to investors in assessing the Company’s financial performance.
Adjusted net income (loss) per diluted share represents adjusted net income (loss) divided by weighted average common shares outstanding on a fully diluted basis.
|
Three Months Ended |
|
Year Ended |
||||||||||||||||||||||||||||
2020 |
|
2019 |
|
2020 |
|
2019 |
|||||||||||||||||||||||||
|
Amount |
|
Per
|
|
Amount |
|
Per
|
|
Amount |
|
Per
|
|
Amount |
|
Per
|
||||||||||||||||
Net income |
$ |
34 |
|
|
$ |
0.56 |
|
|
$ |
168 |
|
|
$ |
2.67 |
|
|
$ |
673 |
|
|
$ |
11.23 |
|
|
$ |
737 |
|
|
$ |
11.47 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Marketplace risk corridor judgment |
(128) |
|
|
(2.15) |
|
|
— |
|
|
— |
|
|
(128) |
|
|
(2.14) |
|
|
— |
|
|
— |
|
||||||||
Acquisition-related expenses (1) |
18 |
|
|
0.31 |
|
|
— |
|
|
— |
|
|
22 |
|
|
0.37 |
|
|
— |
|
|
— |
|
||||||||
Amortization of intangible assets |
4 |
|
|
0.07 |
|
|
4 |
|
|
0.06 |
|
|
16 |
|
|
0.26 |
|
|
17 |
|
|
0.27 |
|
||||||||
Loss (gain) on debt repayment |
10 |
|
|
0.18 |
|
|
— |
|
|
— |
|
|
15 |
|
|
0.26 |
|
|
(15) |
|
|
(0.24) |
|
||||||||
Charitable contribution |
15 |
|
|
0.25 |
|
|
— |
|
|
— |
|
|
15 |
|
|
0.25 |
|
|
— |
|
|
— |
|
||||||||
Restructuring costs |
1 |
|
|
0.01 |
|
|
1 |
|
|
0.02 |
|
|
10 |
|
|
0.16 |
|
|
6 |
|
|
0.10 |
|
||||||||
Premium deficiency reserve - |
(4) |
|
|
(0.07) |
|
|
— |
|
|
— |
|
|
6 |
|
|
0.10 |
|
|
— |
|
|
— |
|
||||||||
Subtotal, adjustments |
(84) |
|
|
(1.40) |
|
|
5 |
|
|
0.08 |
|
|
(44) |
|
|
(0.74) |
|
|
8 |
|
|
0.13 |
|
||||||||
Income tax effect |
20 |
|
|
0.33 |
|
|
(1) |
|
|
(0.02) |
|
|
11 |
|
|
0.18 |
|
|
(2) |
|
|
(0.03) |
|
||||||||
Adjustments, net of tax |
(64) |
|
|
(1.07) |
|
|
4 |
|
|
0.06 |
|
|
(33) |
|
|
(0.56) |
|
|
6 |
|
|
0.10 |
|
||||||||
Adjusted net (loss) income |
$ |
(30) |
|
|
$ |
(0.51) |
|
|
$ |
172 |
|
|
$ |
2.73 |
|
|
$ |
640 |
|
|
$ |
10.67 |
|
|
$ |
743 |
|
|
$ |
11.57 |
|
__________________ (1) Beginning in the third quarter of 2020, reflects non-recurring costs associated with acquisitions, including various transaction and integration costs. |
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES CONTINUED
Normalized EPS represents adjusted EPS, as shown in the reconciliation of GAAP EPS to non-GAAP adjusted EPS, excluding the net effect of COVID. The net effect of COVID consists of discrete premium refunds, reduced demand for medical services, and the cost of COVID-related care. This non-GAAP financial measure should be considered a supplement to, and not a substitute for, GAAP earnings per diluted share. The Company believes this metric, which is used by management in the operation of the business, is helpful to investors in assessing the Company’s 2020 financial performance and operations without the temporary distortion caused by the COVID pandemic.
Normalized after-tax margin represents adjusted net income, excluding the net effect of COVID, divided by total revenue.
|
Three Months
|
|
Year Ended |
||||
|
|
||||||
|
|
|
|
||||
|
(Per diluted share) |
||||||
GAAP EPS – Diluted |
$ |
0.56 |
|
|
$ |
11.23 |
|
Less: Adjustments, net of tax |
(1.07) |
|
|
(0.56) |
|
||
Adjusted EPS – Diluted |
(0.51) |
|
|
10.67 |
|
||
Add: Net effect of COVID |
3.80 |
|
|
2.30 |
|
||
Normalized EPS – Diluted |
$ |
3.29 |
|
|
$ |
12.97 |
|
|
|
|
|
|
|||||||||||||||
2021 GUIDANCE |
|||||||||||||||
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES |
|||||||||||||||
(In millions, except per diluted share amounts) |
|||||||||||||||
|
|
|
|
||||||||||||
|
Low End |
|
High End |
||||||||||||
|
Amount |
|
Per
|
|
Amount |
|
Per
|
||||||||
Net income |
$ |
649 |
|
|
$ |
11.10 |
|
|
$ |
678 |
|
|
$ |
11.60 |
|
Adjustments: |
|
|
|
|
|
|
|
||||||||
Acquisition-related expenses |
62 |
|
|
1.06 |
|
|
62 |
|
|
1.06 |
|
||||
Amortization of intangible assets |
45 |
|
|
0.77 |
|
|
45 |
|
|
0.77 |
|
||||
Subtotal, adjustments |
107 |
|
|
1.83 |
|
|
107 |
|
|
1.83 |
|
||||
Income tax effect (1) |
(26) |
|
|
(0.43) |
|
|
(26) |
|
|
(0.43) |
|
||||
Adjustments, net of tax |
81 |
|
|
1.40 |
|
|
81 |
|
|
1.40 |
|
||||
Adjusted net income |
$ |
730 |
|
|
$ |
12.50 |
|
|
$ |
759 |
|
|
$ |
13.00 |
|
__________________ (1) Income tax effect calculated at the statutory tax rate of 23.9%. (2) Computation assumes approximately 58.5 million diluted weighted average shares outstanding. |
Adjusted G&A Ratio represents the GAAP G&A ratio, recognizing adjustments.
Adjusted after-tax margin represents adjusted net income, divided by total revenue.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005930/en/
Investor Contact:
Media Contact:
Source: